REPL - Rasio utang marang kapitalisasi buku Replimune Group, Inc.

This chart of the market valuation for Replimune Group, Inc. (REPL) is based on the 1.14 metric. The business relies on modified viruses that attack tumors, expanding the patient pool through new diagnoses pending an FDA verdict. Replimune Group, Inc. (REPL) acts as a leader in developing targeted cancer eradication tools, leveraging a powerful R&D base. However, global conflicts are hindering biomaterial logistics and disrupting clinical trial timelines.

REPL Replimune Group, Inc.: Rasio utang marang kapitalisasi buku ing interval 04.07.2022 - 27.10.2026

Ringkesan rincian data analitis Replimune Group Inc (REPL)

- rega lan prakiraan konsensus rega:

Rega saham Replimune Group, Inc.|REPL - Target konsensus

- data kapitalisasi pasar:

Nilai pasar Replimune Inc.|REPL - Total Nilai Perusahaan

- data kapitalisasi buku:

Aset Bersih saben Siji Saham Replimune|REPL - Nilai Buku Perusahaan|Rasio Nilai Pasar marang Nilai Buku replimune.com|REPL - Aset Perusahaan

- data utang lan likuiditas:

Total Utang marang Modal Replimune Group, Inc.|REPL - Tanggungan utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang ekuitas Replimune Corp|REPL - Utang kumulatif perusahaan|Utang marang nilai buku Replimune Inc.

Analisis kabeh metrik perusahaan:REPL, Replimune Group, Inc.

Replimune Group, Inc. (REPL) develops innovative oncolytic viruses based on the RPx platform for the selective destruction of tumors and the activation of the immune response. By analyzing the trajectory of the company's financial leverage on GURU.Markets, an investor assesses the ratio of borrowed funds to the market value of equity, which allows for the identification of asset undervaluation or the risk of business overheating when preparing for a potential acquisition.

Pesaing Replimune Group, Inc.